DETECT III - A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells.

Category Primary study
JournalCANCER RESEARCH
Year 2011
This article has no abstract
Epistemonikos ID: ce5fad793af5c1b4a2cb16b2b5d26ce218ee16db
First added on: Feb 05, 2025